Table 1.
Summary of publications on pulmonary hepatoid adenocarcinoma cases.
| First Author, Year | Country | Sex | Age (Years) | Smoking (pack-year) |
Location | Size(cm) | AFP | TNM | Treatment | Survival/ State |
|---|---|---|---|---|---|---|---|---|---|---|
| (1) Yasunami R, 1981 | Japan | M | 67 | N/A | LUL | 8 | AFP↑ | pT4N0M0 (IIIA) | R, I, C | 16 months/dead |
| (2) Miyake M, 1986 | Japan | M | 55 | N/A | RUL | 5 | AFP↑ | pT4N2M1c (IVB) | RS | 0.13 months/dead |
| (3) Tamura T, 1986 | Japan | M | 80 | 41 | LLL | 4.1 × 3.5 | AFP↑ | cT4N3M1a (IVA) | C | 36 months/alive |
| (4) Miyake M, 1987 | Japan | M | 73 | N/A | LUL | 5 × 6 × 5 | AFP↑ | pT3N2M0 (IIIB) | RS, R | 18 months/dead |
| (5) Saka H, 1988 |
Japan | M | 73 | N/A | RUL | 3.9 × 3 × 3 | AFP↑ | pT2aN0M0 (IB) | RS | 28 months/alive |
| (6) Kurimoto I, 1989 | Japan | M | 75 | 40 | RUL | 5 | AFP↑ | cT3N2M0 (IIIB) | N/A | N/A |
| (7) Okunaka T, 1992 | Japan | M | 49 | Yes | RUL | 6 | AFP↑ | eT3 | RS | 11 months/alive |
| (8) Yoshino I, 1996 | Japan | M | 54 | N/A | RUL | 2 | AFP↑ | pT1bN0M0 (IA2) | RS | 24 months/alive |
| (9) Hirota F, 1999 |
Japan | M | 80 | 45 | RLL | 5 × 4 | AFP↑ | pT2bN2M1b (IVA) | C | 10 months/alive |
| (10) Carlinfante G, 2000 | Italy | M | 65 | Yes | LLL | 3.5 | N/A | pT2aN0M0 (IB) | RS | 84 months/alive |
| (11) Genova S, 2001 | Plovdiv | M | 71 | N/A | LUL | 7.7 × 6.4 | N/A | pT4N0M0 (IIIA) | RS | 24 months/alive |
| (12) Hayashi Y, 2002 | Japan | M | 55 | 87.5 | RUL | 5 × 4.8 × 6.5 | N/A | pT3N0M0 (IIB) | RS | 32 months/alive |
| (13) Terracciano LM, 2003 | Switzerland | M | 49 | N/A | LLL | 5 | AFP↑ | pT2bN0M0 (IIA) | RS | 2 months/dead |
| (14) Oshiro Y, 2004 | Japan | M | 76 | N/A | RLL | 18 × 17 × 12 | N/A | pT4N0M0 (IIIA) | RS | 18 months/dead |
| (15) Ivan M, 2007 |
Canada | M | 54 | 40 | LUL + RUL | (13 × 11) + (3.3 × 2.6) | AFP↑ | pT4N2bM1b (IVA) | C, R | N/A |
| (16) Kishimoto T, 2008 | Japan | M | 64 | N/A | LLL | 7.5 × 7 × 4 | AFP↑ | cT4N0M0 (IIIA) | RS | N/A |
| (17) Li CJ, 2008 | China | M | 65 | N/A | RLL | 6 | AFP↑ | cT4N2M1 (IVA) | TACE, TCM | 16 months/dead |
| (18) Fornasa F, 2010 | Italy | F | 68 | No | LUL | 4.5 × 4 × 4 | AFP→ | pT2bN0M1 (IVA) | C | 15 months/alive |
| (19) Kitada M, 2011 | Japan | M | 69 | 90 | RLL | 6.5 | AFP↑ | pT3N2M0 (IIIB) | RS, C | 12 months/alive |
| (20) Mokrim M, 2012 | Morocco | M | 52 | 20 | LUL | 11.8 × 12 × 8 | AFP↑ | cT4N1M0 (IIIA) | C | 7 months/alive |
| (21) Papatsimpas G, 2012 | Greece | M | 48 | N/A | RUL | 20 × 11 × 8 | AFP↑ | cT4N2bM0 (IIIB) | C, R | 6 months/dead |
| (22) Valentino F, 2012 | Italy | M | 71 | No | RLL | 2.8 and 1.9 | AFP↑ | pT3N3M1b (IVA) | C, R, RS, bevacizumab | 14 months/dead |
| (23) Cavalcante LB, 2013 | Brazil | M | 66 | 40 | RLL | 5 × 3 | N/A | pT2bN0M0 (IIA) | Supportive treatment | 0.4 months/dead |
| (24) Che YQ, 2014 |
China | M | 66 | 70 | LUL | 5.3 × 4.6 and 7.9 × 10.0 |
AFP↑ | pT4N0M0 (IIIA) | C, R | 36 months/dead |
| (25) Haninger DM, 2014 | America | M | 51 | 45 | RUL | 4.2 × 3.7 | N/A | cT2bN3M0 (IIIB) | No | 14 months/dead |
| (25) Haninger DM, 2014 | America | M | 52 | 40 | RUL | 2.5 | N/A | pT1cN0M1c (IVB) | No | 37 months/alive |
| (25) Haninger DM, 2014 | America | M | 64 | 75 | LUL | 3.2 × 2.2 | N/A | pT2aN0M1b (IVA) | No | 10 months/dead |
| (25) Haninger DM, 2014 | America | F | 54 | 35 | LUL | 1 | N/A | pT1aN0M1b (IVA) | C, R | 108 months/alive |
| (25) Haninger DM, 2014 | America | M | 60 | 40 | RUL | 11.2 × 10.1 × 8.5 | AFP↑ | cT4N2M1b (IVA) | No | 1 months/alive |
| (26) Shaib W, 2014 |
America | F | 53 | 40 | RUL | 9.5 × 9.0 × 8.0 | AFP↑ | pT4N0M0 (IIIA) | RS, C | 48 months/alive |
| (27) Al-Najjar H, 2015 | England | M | 71 | 30 | RLL | Multiple | AFP↑ | cT4N3M1a (IVA) | C | 12 months/dead |
| (28) Gavrancic T, 2015 | America | M | 64 | N/A | RUL | 3.8 × 2.9 | AFP↑ | cT2aN2M1 (IVA) | C, Sorafenib, R | 11 months/dead |
| (29) Grossman Kate, 2016 | America | M | 54 | Yes | RUL | 5.1 × 4.1 | AFP→ | cT3N0M1b (IVA) | C, R | 3 months/dead |
| (30) Qian GQ, 2016 | China | M | 79 | 50 | RUL | 2.7 × 2.6 | AFP↑ | cT1cN0M0 (IA3) | Erlotinib | 0.83 months/dead |
| (31) Sun JN, 2016 |
China | M | 59 | Yes | RUL | 4.5 × 3.5 × 3.5 | N/A | pT2bN0M0 (IIA) | RS | 23 months/alive |
| (32) Wang S, 2016 |
China | M | 56 | N/A | RUL | 4.0 × 4.1 × 4.8 | N/A | cT4N1M0 (IIIA) | N/A | N |
| (33) Basse V, 2018 |
France | M | 43 | 8 | N/A | N/A | N/A | cTxN3M1c (IVB) | C, durvalumab anti- PD-L1 therapy | dead without following time |
| (34) Esa NYM, 2018 | Malaysia | M | 50 | 40 | LUL | 6 × 5 × 6 | AFP↑ | IIIB | R, C | 7 months/dead |
| (35) Li Q, 2018 |
China | M | 52 | 60 | RUL | N/A | N/A | cT2N2M0 (IIIA) | C, R | 2 months/dead |
| (36) Nakashima K, 2018 | Japan | M | 60 | 40 | RUL | 6.3 × 4.8 | AFP↑ | pT3N0M0 (IIB) | RS | 8 months/alive |
| (37) Ruiz CD, 2018 |
N/A | F | 69 | 70 | LUL | 8 × 8 × 5 | AFP→ | cT4N1M0 (IIIA) | R | 1 months/dead |
| (38) Ayub A, 2019 |
America | M | 61 | 40 | RUL | 2.3 | N/A | pT1cN0M0 (IA3) | RS, R | 6 months/dead |
| (39) Chen HF, 2019 | China | M | 53 | No | RUL | 5.3 × 3.5 | AFP↑ | pT3N0M0 (IIB) | RS, C, R, Icotinib, Osimertinib, Anlotinib |
36 months/alive |
| (39) Chen Y, 2019 |
China | M | 47 | 45 | RLL | 9.7 × 6.1 × 6.9 | AFP→ | cT4N3M1c (IVB) | C | 2 months/dead |
| (40) EI Khoury A, 2019 | England | M | 59 | >30 | RUL | 9.3 × 7.2 × 6.8 | N/A | cT4N2M1b (IVA) | C | 14 months/alive |
| (41) Kuan K, 2019 |
America | M | 47 | Yes | RUL | 14 | N/A | cT4N0M0 (IIIA) | RS | 4 months/dead |
| (42) Li J, 2019 |
China | M | 71 | No | RLL | 7 × 4.5 | AFP↑ | cT3N3M1b (IVA) | R | 5.5 months/dead |
| (43) Malik SA, 2019 | N/A | F | 56 | Yes | RLL | 2 × 2 | AFP→ | N/A | N/A | 2 months/dead |
| (44) Shi YF, 2019 |
China | M | 60 | No | RUL | 7 × 7 × 5 | AFP↑ | pT3N2M0 (IIIB) | RS, C | 15 months/dead |
| (45) Wang C, 2019 |
China | M | 70 | 50 | RUL | 6.0 × 4.6 | N/A | cT3N2M0 (IIIB) | C, R, Bevacizumab | 9 months/dead |
| (46) Yang K, 2019 |
China | M | 70 | 120 | LLL | 6 × 6 × 5.5 | N/A | pT3N1M0 (IIIA) | RS | 18 months/dead |
| (47) Chen JX, 2020 |
China | M | 63 | N/A | LLL+RUL | N/A | N/A | pT4N3M1c (IVB) | N/A | 4 months/dead |
| (48) Chen LL, 2020 |
China | F | 65 | No | LL+RL | (7 × 5.1) + (9.2 × 4.6) |
AFP↑ | pT4NxM1b (IVA) | C, Bevacizumab, Anlotinib, Sintilimab | 53 months/dead |
| (49) Muroyama Y, 2020 | America | M | 66 | 30 | LUL | 8 × 5 | AFP↑ | T4N3M1b | C+R | 19 months/dead |
| (50) Tonyali O, 2020 | Turkey | F | 62 | Yes | LUL | 8 × 7 × 7 and 3 × 2.5 × 2 |
AFP↑ | T4N1M0 | RS +C+I+R | 14 months/dead |
| (51) Chen Z, 2022 |
China | M | 67 | Yes | RML | 7.1 × 5.3 | AFP→ | T4N1M0 | C+ RS | 13 months/dead |
| (52) Xu S, 2022 |
China | M | 55 | 70 | LUL | 8.46 × 6.53 | AFP↑ | cT4N3M1a (IVA) | C+I | 13 months/alive |
| (53) Yao Y, 2022 |
China | M | 63 | N/A | LUL | 7.5 × 5.5 | AFP↑ | T4N0M0(IIIA) | RS | 6 months/dead |
| (54) Galina G, 2022 | America | M | 54 | 25 | RLL | Multiple (max = 14) |
AFP↑ | cT4N0M0 (IIIA) | C+I | 7 months/alive |
| (55) Hou Z, 2021 |
China | M | 66 | Yes | RUL | 3.3 × 2.5 × 4.0 | AFP↑ | cT2N2MO(IIIA) | C, R, Sorafenib +Sintilimab |
13 months/dead |
| This report | China | M | 65 | Yes | LUL | 16.0 × 9.0 × 3.0 (2.2 × 1.7 × 1.5) | AFP↑ | cT1cN2aM0 (IIIA) | RS +C+Sintilimab | 6 months/alive |
*M, Male; F, Female; RS, radical surgery; C, chemotherapy; I, Immunotherapy; R, Radiotherapy; LL, left lobe; RL, right lobe; LUL, left upper lobe; RUL, right upper lobe; RLL, right lower lobe; LLL, left lower lobe; RML, Right middle lobe; AFP, Alpha Fetoprotein; N/A, Not applicable.